GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » Price-to-Owner-Earnings

Chiome Bioscience (TSE:4583) Price-to-Owner-Earnings : (As of Dec. 12, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience Price-to-Owner-Earnings?

As of today (2024-12-12), Chiome Bioscience's share price is 円228.00. Chiome Bioscience does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Chiome Bioscience's Price-to-Owner-Earnings or its related term are showing as below:


TSE:4583's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.745
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-12-12), Chiome Bioscience's share price is 円228.00. Chiome Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was 円-21.13. Therefore, Chiome Bioscience's PE Ratio (TTM) for today is At Loss.

As of today (2024-12-12), Chiome Bioscience's share price is 円228.00. Chiome Bioscience's EPS without NRI for the trailing twelve months (TTM) ended in was 円-21.17. Therefore, Chiome Bioscience's PE Ratio without NRI for today is At Loss.


Chiome Bioscience Price-to-Owner-Earnings Historical Data

The historical data trend for Chiome Bioscience's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience Price-to-Owner-Earnings Chart

Chiome Bioscience Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Chiome Bioscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Chiome Bioscience's Price-to-Owner-Earnings

For the Biotechnology subindustry, Chiome Bioscience's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chiome Bioscience's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's Price-to-Owner-Earnings falls into.



Chiome Bioscience Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Chiome Bioscience's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=228.00/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chiome Bioscience  (TSE:4583) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Chiome Bioscience Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Chiome Bioscience Business Description

Traded in Other Exchanges
N/A
Address
Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience Headlines

No Headlines